Mechanisms of anticancer drugs

Scott-Brown's Otorhinolaryngology: Head and Neck Surgery

Volumn , Issue , 2008, Pages 81-93

  Payne, Sarah ^a   Miles, David ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85137711731     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (28)

1. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anti-cancer agents. XIII On the criteria and kinetics associated with 'curability' of experimental leukaemia. Cancer Chemotherapy Reports. 1964; 35: 1-111.
2. Herscher LL, Cook J. Taxanes as radiosensitizers for head and neck cancer. Current Opinion in Oncology. 1999; 11: 183-6.
3. Guichard SM, Danks MK. Topoisomerase enzymes as drug targets. Current Opinion in oncology. 1999; 11: 482-9.
4. Henk JM. Concomitant chemotherapy for head and neck cancer: saving lives or grays? Clinical Oncology (Royal College of Radiologists (Great Britain)). 2001; 13: 333-5.
5. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000; 355: 949-55.
6. Forastiere A, Koch W, Trotti A, Sidransky D. Head and Neck Cancer. New England Journal of Medicine. 2001; 345: 1890-1900.
7. Haffty BG. Concurrent chemoradiation in the treatment of head and neck cancer. Hematology/Oncology Clinics of North America. 1999; 13: 719-42.
8. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R et al. 13-Cis retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine. 1986; 315: 1501-5.
9. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM et al. Prevention of second primary tumours with isotretinoin in squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 1990; 323: 795-801.
10. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Research. 1999; 59: 991-4.
11. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumours. Cancer Treatment Reviews. 2000; 26: 269-86.
12. Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head and Neck. 1998; 20: 320-7.
13. Mauizi M, Almadori G, Ferrandina G, Distefano M, Romanini M, Cadoni G et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. British Journal of Cancer. 1996; 74: 1253-7.
14. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research. 1999; 5: 257-64.
15. Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. European Journal of Cancer. 2001; 37: S16-22.
16. Wheeler RH, Spencer S, Buchsbaum D, Robert F. Monoclonal antibodies as potentiators ofradiotherapyand chemotherapy in the management of head and neck cancer. Current Opinion in Oncology. 1999; 11: 187-190.
17. Saleh M, Buchsbaum D, Meredith R, Lalison D, Wheeler R. In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the epidermal growth factor receptor. Proceedings for the American Association for Cancer Research. 1996; 37:612 (Abstr. 4197).
18. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Seminars in Oncology. 2002; 29: 27-36.
19. Cohen EE, Rosen F, Stadler WM, Recant WM, Stenson K, Huo D et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. May 15, 2003; 21: 1980-7.
20. Caponigro F. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer. Anticancer Drugs. April, 2004; 15: 311-20.
21. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park, NY). 2003; 17: 23-8.
22. Folkman J. Seminars in Medicine of Beth Israel Hospital, Boston. Clinical application of research on angiogenesis. New England Journal of Medicine. 1995; 333: 1757-63.
23. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic treatment of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390: 404-7.
24. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Modern Pathology. 2005; 18: 485-94.
25. Hurwitz H, Fehrenbacker L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine. 2004; 350: 2335-42.
26. Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Current Opinion in Oncology. 2005; 17: 212-7.
27. Caponigro F, Basile M, de Rosa V, Normanno N. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs. 2005; 16: 211-21.
28. Dancey J, Arbuck S. Cancer Drugs and Cancer Drug Development for the New Millennium. In: Khayat D, Hortobagyi GN (eds). Progress in anti-cancer chemotherapy, Volume IV. 2000: 91-107.